Javier Kamisato, MD
Internal Medicine · Las Vegas, NVNPI 1902943434
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,344 of the $11,576 with a category attached, or 89.4%. 32 manufacturers reported payments, led by AstraZeneca at 25.7% of the total. Among internal medicine clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $40.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Biohaven Pharmaceuticals, Inc.$1K
- Amgen$1K
- AbbVie$750
- Amarin Pharma, Inc.$612
- Johnson & Johnson$468
- plus $4K from 26 others
What the payments were for
- Consulting fees$1,20010%
- Food & beverage$10,34489%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 73 | $2,975 |
| Biohaven Pharmaceuticals, Inc. | 5 | $1,472 |
| Amgen | 31 | $1,210 |
| AbbVie(2 entities) | 14 | $750 |
| Amarin Pharma, Inc. | 27 | $612 |
| Johnson & Johnson | 10 | $468 |
| Novo Nordisk | 8 | $467 |
| Vanda Pharmaceuticals Inc. | 24 | $391 |
| Radius Health, Inc. | 4 | $344 |
| Otsuka America Pharmaceutical, Inc. | 6 | $324 |
| Astellas Pharma US Inc | 7 | $291 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $281 |
| GSK | 7 | $259 |
| Lilly USA, LLC | 12 | $236 |
| Merck | 8 | $146 |
| Daiichi Sankyo Inc. | 3 | $144 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Bayer | 2 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $121 |
| Mannkind Corporation | 6 | $102 |
| Sanofi-aventis U.S. LLC | 4 | $99 |
| Silk Road Medical, Inc. | 1 | $97 |
| Recordati_rare_diseases_inc. | 1 | $88 |
| Boehringer Ingelheim | 4 | $81 |
| Bausch Health US, LLC | 3 | $78 |
| Genentech USA, Inc. | 4 | $71 |
| Pfizer | 3 | $54 |
| Novartis | 2 | $50 |
| Abbott | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,576 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 46 | $57,854 |
| TrulicityDulaglutide | 24 | $39,905 |
| EliquisApixaban | 19 | $27,486 |
| OzempicSemaglutide | 12 | $24,403 |
| XareltoRivaroxaban | 16 | $24,113 |
| MyrbetriqMirabegron | 12 | $14,861 |
| VascepaIcosapent Ethyl | 19 | $12,991 |
| Xigduo XrDapaglifloz Propaned/Metformin | 18 | $10,263 |
| Repatha SureclickEvolocumab | 16 | $10,202 |
| JardianceEmpagliflozin | 12 | $7,423 |
| Humulin NInsulin Nph Human Isophane | 31 | $3,511 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,956 |
| Atorvastatin Calcium | 304 | $2,757 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 14 | $2,181 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 11 | $1,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $2,975 | $57,85446 claims |
| Lilly USA, LLCTrulicity, Humulin N, Humulin 70-30 | $236 | $45,59769 claims |
| PfizerEliquis | $54 | $27,48619 claims |
| Novo NordiskOzempic | $467 | $24,40312 claims |
| Johnson & JohnsonXarelto | $468 | $24,11316 claims |
| Astellas Pharma US IncMyrbetriq | $291 | $14,86112 claims |
| Boehringer IngelheimJardiance | $81 | $7,42312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Las Vegas
- Kevin DunsmoorLas Vegas$241K
- Robert ChiascioneLas Vegas$174K
- Dino GonzalezLas Vegas$126K
- Rosanne SugayLas Vegas$63K
- Chad HallLas Vegas$42K
- Zubin DamaniaLas Vegas$40K
- Audrey Sue CruzLas Vegas$34K
- Bashab BanerjiLas Vegas$26K
- Amaan ShafiLas Vegas$25K
- Sassan KavehLas Vegas$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.